Early Rheumatoid Arthritis Clinical Trial
Official title:
A Phase Ib Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GCK in Rheumatoid Arthritis Patients
This is a phase Ib study to investigate the safety, pharmacokinetics and preliminary efficacy of ginsenoside compound K (GCK) tablets in patients with rheumatoid arthritis. This study is to be run in China involving 10-12 sites. It will enroll approximately 240 patients to ensure 128 randomized with active rheumatoid arthritis. The treatment period is 12 weeks and total study duration per patient is approximately 14 weeks.
In this double-blind, placebo-controlled, phase Ib study, 128 patients with active RA are planned to be enrolled and randomly assigned 1:1:1:1 to receive placebo, or different doses of GCK tablet (100/200/300 mg). This study will evaluate the safety, pharmacokinetics and preliminary efficacy of GCK tablets in patients with rheumatoid arthritis ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01768923 -
Early RA Vascular Randomised Controlled Study
|
N/A | |
Completed |
NCT01762176 -
Early RA MRI Early Intensive Treatment Study
|
N/A | |
Completed |
NCT01185301 -
Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)
|
Phase 3 | |
Recruiting |
NCT03389711 -
INCMNSZ - Rheumatoid Arthritis Cohort
|
||
Completed |
NCT00195663 -
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT04752748 -
Power Doppler in Hand Joints of Early RA Patients
|